RWS of Inetetamab HER2 Positive Advanced Breast Cancer
NCT04963608 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-07-15
Summary
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
Conditions
- HER2-positive Advanced Breast Cancer
Interventions
- DRUG
-
Inetetamab
8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
Sponsors & Collaborators
-
Zhiyong Yu
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-31
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
More Related Trials
-
Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
NCT05444998 ·Status: UNKNOWN ·Phase: PHASE2
-
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
NCT05367739 ·Status: COMPLETED
-
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors
NCT04146610 ·Status: UNKNOWN ·Phase: PHASE1
-
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
NCT05945368 ·Status: UNKNOWN ·Phase: PHASE2
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
NCT06340165 ·Status: RECRUITING
-
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
NCT06495541 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
B002 in Patients With HER2-positive Breast Cancer
NCT04382352 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer
NCT05149014 ·Status: COMPLETED
-
Dalpiciclib in HR+/HER2- ABC
NCT06301438 ·Status: RECRUITING
-
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
NCT03052634 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
NCT04158505 ·Status: UNKNOWN
-
Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP
NCT04929548 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
NCT04681287 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612 ·Status: RECRUITING
-
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
NCT05263869 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05035836 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
NCT02481050 ·Status: COMPLETED ·Phase: PHASE2
-
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
NCT06481553 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961 ·Status: RECRUITING ·Phase: PHASE3
-
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
NCT06711055 ·Status: RECRUITING
-
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
NCT05532696 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369 ·Status: RECRUITING
-
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04254263 ·Status: RECRUITING ·Phase: PHASE3
-
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
NCT06784921 ·Status: RECRUITING